Lupin Ltd has acquired Mexico’s speciality pharmaceutical company Laboratorios Grin, for an undisclosed sum. The move marks Lupin’s entry into the Mexican and larger Latin American market.
Mexico is one of the fast-growing pharmaceutical markets, valued at over $13.5 billion and growing at 9-10 per cent annually.
Incorporated in 1955, Grin makes and sells branded ophthalmic products, and recorded revenues of approximately $28 million in 2013. The company has over 275 employees.
Vinita Gupta, Lupin’s Chief Executive Officer, said the acquisition is a reflection of Lupin’s commitment to expand into the Latin American market and build its global specialty business. “We see a lot of synergies in this acquisition and plan to bring our ophthalmic pipeline to build the Grin business as well as leverage their commercial presence to enter other promising therapy segments,” she said in a company statement.
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…